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Abstract 
Background: The sodium–glucose cotransporter‑2 (SGLT2) inhibitor canagliflozin has been shown to reduce major 
cardiovascular events in type 2 diabetic patients, with a pronounced decrease in hospitalization for heart failure (HF) 
especially in those with HF at baseline. These might indicate a potent direct cardioprotective effect, which is currently 
incompletely understood. We sought to characterize the cardiovascular effects of acute canagliflozin treatment in 
healthy and infarcted rat hearts.
Methods: Non‑diabetic male rats were subjected to sham operation or coronary artery occlusion for 30 min, fol‑
lowed by 120 min reperfusion in vivo. Vehicle or canagliflozin (3 µg/kg bodyweight) was administered as an intrave‑
nous bolus 5 min after the onset of ischemia. Rats underwent either infarct size determination with serum troponin‑T 
measurement, or functional assessment using left ventricular (LV) pressure–volume analysis. Protein, mRNA expres‑
sions, and 4‑hydroxynonenal (HNE) content of myocardial samples from sham‑operated and infarcted rats were inves‑
tigated. In vitro organ bath experiments with aortic rings from healthy rats were performed to characterize a possible 
effect of canagliflozin on vascular function.
Results: Acute treatment with canagliflozin significantly reduced myocardial infarct size compared to vehicle 
(42.5 ± 2.9% vs. 59.3 ± 4.2%, P = 0.006), as well as serum troponin‑T levels. Canagliflozin therapy alleviated LV systolic 
and diastolic dysfunction following myocardial ischemia–reperfusion injury (IRI), and preserved LV mechanoenerget‑
ics. Western blot analysis revealed an increased phosphorylation of adenosine monophosphate‑activated protein 
kinase (AMPK) and endothelial nitric‑oxide synthase (eNOS), which were not disease‑specific effects. Canagliflozin 
elevated the phosphorylation of Akt only in infarcted hearts. Furthermore, canagliflozin reduced the expression of 
apoptotic markers (Bax/Bcl‑2 ratio) and that of genes related to myocardial nitro‑oxidative stress. In addition, treated 
hearts showed significantly lower HNE positivity. Organ bath experiments with aortic rings revealed that preincuba‑
tion with canagliflozin significantly enhanced endothelium‑dependent vasodilation in vitro, which might explain the 
slight LV afterload reducing effect of canagliflozin in healthy rats in vivo.
Conclusions: Acute intravenous administration of canagliflozin after the onset of ischemia protects against myo‑
cardial IRI. The medication enhances endothelium dependent vasodilation independently of antidiabetic action. 
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Background
Sodium–glucose cotransporter-2 (SGLT2) inhibitors are 
novel antidiabetic agents prescribed for a growing num-
ber of patients with type 2 diabetes mellitus (T2DM) 
worldwide. Recently, the landmark EMPA-REG OUT-
COME clinical trial [1] reported that the SGLT2 inhibitor 
empagliflozin, when added to standard care, significantly 
reduced the risk of major cardiovascular events (the 
composite of death from cardiovascular causes, non-fatal 
myocardial infarction and non-fatal stroke) compared to 
placebo (hazard ratio [HR], 0.86; 95% confidence inter-
val [CI] 0.74–0.99; P = 0.04). The CANVAS Program [2] 
reported a similar effect on the composite outcome with 
the SGLT2 inhibitor canagliflozin in T2DM patients with 
high cardiovascular risk (HR, 0.86; 95% CI 0.75–0.97; 
P = 0.02). Furthermore, hospitalization for heart fail-
ure (HF) was robustly reduced in canagliflozin-treated 
T2DM patients compared to placebo (HR, 0.67; 95% CI 
0.52–0.87) [2] and those with pre-existing HF at base-
line derived more benefit [3]. Interestingly, canagliflo-
zin-treated patients were just as likely to suffer an acute 
myocardial infarction as the placebo group but had a 
higher chance of surviving such event [2]. These findings 
support the notion that canagliflozin might have a direct 
cardiovascular protective effect independently of its anti-
diabetic action, the mechanism of which is incompletely 
understood [4, 5].
In recent preclinical studies, it was reported that cana-
gliflozin potently activates adenosine monophosphate 
(AMP)-activated protein kinase (AMPK) in  vitro [6], 
directly inhibits sodium–hydrogen exchanger (NHE) in 
non-diabetic healthy hearts [7], and has a direct vasodila-
tory effect under diabetic conditions [8, 9]. However, it is 
currently unknown whether acute intravenous adminis-
tration of canagliflozin has a direct cardiovascular effect 
independently of antidiabetic action. Accordingly, in the 
current investigation we sought to characterize the car-
diovascular effects of acute intravenous canagliflozin in 
healthy and infarcted rats.
Methods
Animals
Seven-week-old, non-diabetic male Sprague–Dawley 
rats (body weight [BW]: 250–350 g; Janvier Labs, France) 
were housed in a room with a constant temperature of 
22 ± 2 °C, 12 h light/dark cycles and were allowed access 
to standard laboratory rat diet and water ad libitum. The 
investigation conformed to the EU Directive 2010/63/
EU and to the Guide for the Care and Use of Labora-
tory Animals published by the US National Institutes of 
Health (NIH Publication No. 85-23, revised 1996). The 
experimental protocol was reviewed and approved by 
the appropriate institutional ethics committee (Refer-
ence No. PEI/001/2374-4/2015). The study is interpreted 
in accordance with the Animal Research: Reporting of 
In Vivo Experiments (ARRIVE) guidelines [10].
Materials
Canagliflozin (10  mmol/L) dissolved in dimethyl sul-
foxide (DMSO) was obtained from Selleck Chemicals 
(Munich, Germany). For the in  vivo studies, this stock 
solution of canagliflozin was diluted 1:1000 in 0.9% 
saline with 1% hydroxyl-propyl-γ-cyclodextrin and was 
administered intravenously (dose: 3 µg/kg BW). The cor-
responding vehicle consisted of DMSO diluted 1:1000 in 
0.9% saline with 1% hydroxyl-propyl-γ-cyclodextrin. The 
final intravenous volume of canagliflozin or vehicle bolus 
was 170–240 µL, varying based on the BW of the given 
rat (67 µL/100 g BW). For the in vitro study with aortic 
rings, the stock solution of canagliflozin was used in case 
of the treatment group, while an equal amount of DMSO 
was applied in the vehicle/placebo treatment group.
Evans blue (#E2129) and triphenyl-tetrazolium-chlo-
ride (TTC; #T8877) were purchased from Sigma Aldrich 
(Darmstadt, Germany) and used as a 1% solution dis-
solved in Tris-buffered saline, respectively.
Primary antibodies against phospho-Akt (Ser473, 
#9271), total-Akt (#9272), phospho-AMPKα (Thr172, 
#2531), total-AMPKα (#2532), phospho-acetyl-CoA 
carboxylase (p-ACC; Ser79, #3661), total-ACC (#3662), 
phospho-eNOS (Ser1177, #9571), total-eNOS (#9572), 
B-cell leukemia/lymphoma 2 (Bcl-2; #2876), and Bcl-2 
associated protein x (Bax; #2772) as well as secondary 
anti-rabbit horseradish peroxidase-linked antibodies 
(#7074) were obtained from Cell Signaling Technology 
(Frankfurt am Main, Germany).
The following TaqMan Gene Expression Assays 
were purchased from Applied Biosystems (Fos-
ter City, CA, USA) and were used for quantitative 
real-time polymerase chain reaction (PCR): Bax (ID: 
Rn02532082_g1); Bcl-2 (ID: Rn99999125_m1); cata-
lase (ID: Rn00560930_m1); the 47  kDa subunit of the 
These findings might further contribute to our understanding of the cardiovascular protective effects of canagliflozin 
reported in clinical trials.
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multiprotein complex nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxidase  (p47phox; ID: 
Rn00586945_m1); superoxide dismutase-2 (SOD-2; ID: 
Rn00690587_g1); ribosomal protein L27 (RPL27; ID: 
Rn00821099_g1).
For immunohistochemical staining, polyclonal rab-
bit anti-HNE (4-hydroxynonenal) antibody (#ab46545) 
was purchased from Abcam, Cambridge, UK. HRP-
conjugated secondary antibody (ImmPRESS HRP Rea-
gent Kit, #MP-7401) and black colored nickel–cobalt 
enhanced diaminobenzidine (#SK4105) were obtained 
from Vector Laboratories, Burlingame, CA, USA.
For organ bath measurements, phenylephrine (PE), 
acetylcholine (ACh), sodium nitroprusside (SNP) and 
potassium chloride (KCl) were purchased from Sigma-
Aldrich (Steinheim, Germany) and dissolved in 0.9% 
sodium chloride (NaCl).
Study design
In the first part of the in  vivo study, non-diabetic rats 
underwent LAD occlusion for 30  min as detailed 
below. Vehicle (IRI, n = 7; BW = 282 ± 6  g) or canagli-
flozin (3  µg/kg BW; IRI + cana, n = 7; BW = 290 ± 4  g) 
was administered as a single intravenous bolus at the 
5th min of ischemia. After 120  min of reperfusion, 
serum troponin-T and myocardial infarct size were 
determined.
In the second part of the in  vivo study, non-diabetic 
rats underwent either sham operation or LAD occlu-
sion for 30  min followed by 120  min reperfusion (IRI) 
as detailed below. Vehicle or canagliflozin (3 µg/kg BW) 
was administered as a single intravenous bolus at the 
5th min of simulated ischemia (in case of sham opera-
tion) or ischemia (in case of LAD occlusion). Accord-
ingly, the following experimental groups participated 
in the study: sham + vehicle (n = 7; BW = 310 ± 10  g); 
sham + canagliflozin (n = 7; BW = 307 ± 11 g); IRI + vehi-
cle (n = 9; BW = 308 ± 10  g); IRI + canagliflozin (n = 10; 
BW = 314 ± 7  g). After 120  min of reperfusion, LV 
function was characterized by pressure–volume (PV) 
analysis. Then, serum and urine samples were taken to 
measure markers of hepatic and renal function. Myocar-
dial samples were conserved for immunohistochemical 
and molecular (protein and mRNA expression) analysis.
In the in  vitro study, we preincubated aortic rings of 
healthy rats (N = 5) with vehicle (DMSO, n = 10 rings) or 
canagliflozin (10 µM; Canagliflozin, n = 10 rings) to test 
direct vascular effect of the medication.
Study protocols
Experimental model of in vivo myocardial ischemia–
reperfusion injury
Prior to experimentations, rats were allowed to acclima-
tize. Regional myocardial IRI was induced by transient 
left anterior descending coronary artery (LAD) ligation 
in  vivo for 30  min, followed by 120  min of reperfusion. 
Briefly, rats were weighed, anesthesia was induced by 
i.p. injection of sodium-pentobarbital (60  mg/kg body-
weight) and was maintained by 15–20  mg/kg reinjec-
tion when required (by frequently checking pain reflex). 
The animals were placed in a supine position on a con-
trolled heating pad to maintain the body temperature at 
37 ± 0.2  °C throughout the whole protocol. The trachea 
was cannulated and connected to a small animal respi-
rator. Animals were ventilated with oxygen. Electrocar-
diographic (ECG) monitoring and serial recording with 
6 leads was applied throughout the whole procedure. 
The left external jugular vein was prepared, and a poly-
ethylene catheter was introduced for intravenous admin-
istration of fluid. Thoracotomy was performed at the 
4th intercostal space (without cutting ribs), which was 
spread with a small animal dissector. The pericardium 
was incised and a 5-0 Prolene suture with a curved nee-
dle was placed around the LAD from the right border of 
the left atrial appendage to the left border of the pulmo-
nary conus, ensuring a universally applicable standard 
height for LAD ligation in rats [11]. A small pledget was 
threaded through the ligature and placed in contact with 
the surface of the myocardium to form a snare. The LAD 
was occluded for 30 min by placing the ligature through a 
small piece of plastic tube and pulling the snare tightly in 
place with a mosquito forceps. Successful occlusion and 
subsequent development of ischemia was confirmed by 
(i) prompt ST-segment changes on ECG with progressive 
ST-segment elevation in at least 3 leads with or without 
arrythmia, and (ii) decolorization of the myocardium dis-
tal to the occlusion. After 30  min of ischemia, the liga-
ture was released and reperfusion was maintained for 
120 min. Restoration of blood flow was confirmed by (i) 
prompt ST-segment changes on ECG with progressive 
ST-segment normalization/depression and pathological 
Q-wave formation in leads with previous ST-segment 
elevation with or without arrythmia, and (ii) re-coloriza-
tion of the affected myocardium.
Control rats underwent sham operation consisting of 
the above procedure except the suture around the LAD 
was not tightened (i.e. no ischemia–reperfusion).
Measurement of myocardial infarct size
In the first part of the in vivo study animals were euthan-
ised following 120  min of reperfusion. The abdominal 
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aorta of the animals was cannulated, arterial blood sam-
ples were collected for serum troponin-T measurement. 
Infusion of 4  °C ringer solution (50  mL) was then per-
formed retrogradely. Then, the suture was retightened 
around the LAD and 1% Evans blue was retrogradely 
injected into the aorta to delineate the area at risk (AAR). 
Hearts were harvested and allowed to freeze at − 20  °C 
before being sliced into 2 mm thick transverse sections in 
a heart matrix (Zivic Instruments; Pittsburgh, USA), after 
which they were incubated in 37 °C 1% triphenyl-tetrazo-
lium-chloride (TTC) for 15 min. Intracellular dehydroge-
nases in the myocardium react with TTC, which results 
in the red staining of the viable area, while the infarcted 
(non-viable) zones remain white. The stained heart slices 
were digitally scanned and evaluated with software plani-
metry by an experienced investigator blinded to the 
experimental design of the study. The area at risk was 
quantified as the percentage of the total ventricular area, 
while infarct size (IS) was expressed as the percentage of 
the AAR.
Left ventricular pressure–volume analysis
In the second part of the in vivo study, PV analysis was 
performed as described previously [12], with a microtip 
pressure-conductance catheter (SPR-838; Millar Instru-
ments, Houston, TX, USA) inserted into the LV via the 
right common carotid artery. For analysis, all PV loops 
were obtained with the ventilator turned off for 5–10  s 
and the animal apnoeic.
Heart rate, end-systolic blood pressure, maximal 
slope of systolic pressure increment (dP/dtmax), arte-
rial elastance, the slope of the end-diastolic PV relation-
ship (EDPVR) and time constant of LV pressure decay 
 (TauWeiss) were calculated with PV analysis software 
(PVAN; Millar Instruments, Houston, TX, USA). Rate-
pressure product (RPP, or double product) was calculated 
as heart rate multiplied by LV systolic pressure.
To detect load-independent sensitive contractility 
parameters, PV loops were also registered during tran-
siently decreasing preload achieved by the transient 
occlusion of the inferior vena cava. Accordingly, the 
slope of the end-systolic PV relationship (ESPVR) and 
preload recruitable stroke work (PRSW) were calculated. 
To assess LV mechanoenergetics, ventriculo-arterial 
coupling (VAC) was calculated as the ratio of arterial 
elastance and ESPVR, and mechanical efficiency was 
computed. After PV measurements, animals were eutha-
nized, the abdominal aorta was cannulated, arterial blood 
samples were collected and 4 °C ringer solution (50 mL) 
was infused retrogradely. Hearts were then harvested, 
and a cross section of the hearts (at the level of the ven-
tricles) was placed in 4% buffered paraformaldehyde for 
the forthcoming immunohistochemical analysis, while 
LV samples taken from the AAR were immediately snap 
frozen in liquid nitrogen for the forthcoming immunob-
lot and PCR measurements.
Western blot analysis
Left ventricular myocardial tissue samples from the AAR 
were lysed mechanically by the Tissue Lyzer LT system 
(Qiagen; Hilden, Germany) and chemically by RIPA 
buffer (Melford, Ipswich, UK) containing protease and 
phosphatase inhibitor cocktail (Roche; Mannheim, Ger-
many). The concentrations of the extracted proteins were 
measured by Bradford assay. Then, protein homogen-
ates were suspended in sample buffer and boiled at 95 °C 
for 5 min. A total of 40 µg protein for each sample was 
loaded onto 6–12% acrylamide gels and separated with 
sodium dodecyl sulfate polyacrylamide gel-electropho-
resis (Peqlab Biotechnologie; Erlangen, Germany). Gels 
were transferred to polyvinylidene fluoride membranes 
(Millipore; Darmstadt, Germany) under semi-dry condi-
tions. Membranes were then washed and blocked for 1 h 
in 5% bovine serum albumin (BSA) in Tris-buffered saline 
Tween 20 (TBST) at room temperature. The membranes 
were incubated overnight at 4 °C with the following pri-
mary antibodies (1:1000, 2.5% BSA in TBST): phospho-
Akt (Ser473), total-Akt, phospho-AMPKα (Thr172), 
total-AMPKα, phospho-ACC (Ser79), total-ACC, 
phospho-eNOS (Ser1177), total-eNOS, Bax and Bcl-2, 
respectively. The blots were washed and incubated with 
horseradish peroxidase- conjugated secondary antibody 
(1:5000, 2.5% BSA in TBST) for 1 h at room temperature. 
The immunoreactive protein bands were developed using 
the Enhanced Chemiluminescence system (PerkinElmer; 
Rodgau-Juegesheim, Germany). The intensity of the 
immunoblot bands was analyzed with Chemi-smart 5100 
(Peqlab Biotechnologie).
Quantitative real‑time polymerase chain reaction
Left ventricular myocardial tissue samples from the AAR 
were homogenized, total RNA was isolated by using 
RNeasy Fibrous Tissue Kit (Qiagen; Hilden, Germany) 
according to the manufacturer’s instructions. RNA con-
centration was measured photometrically at 260  nm, 
RNA purity was ensured by obtaining a 260/280  nm 
optical density ratio of ∼ 2.0 and RNA was reverse tran-
scribed to cDNA with QuantiTect Reverse Transcription 
Kit (Qiagen) by using 1 μg RNA of each sample and ran-
dom primers. After that, qRT-PCR was performed on a 
StepOnePlus RT PCR System (Applied Biosystems; Fos-
ter City, CA, USA) using TaqMan Universal PCR Mas-
terMix and TaqMan Gene Expression Assays (Applied 
Biosystems). Every sample was quantified in triplicates 
in a volume of 10  μL in each well containing cDNA 
(1 μL). The following targets were investigated: Bax; Bcl2; 
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catalase; SOD-2;  p47phox. Data were normalized to the 
housekeeping RPL27. Gene expression levels were calcu-
lated using the comparative method  (2−ΔCT).
Immunohistochemistry
Heart samples of the harvested hearts were fixed in 4% 
buffered paraformaldehyde for 24 h, embedded in paraf-
fin and 5 µm thick sections were cut.
In order to asses myocardial oxidative stress, stain-
ing for HNE was performed. After deparaffinization 
and antigen retrieval (0.1 mmol/L citrate buffer, pH = 3, 
heating in microwave oven for 15  min) sections were 
incubated with polyclonal rabbit anti-HNE antibody 
(1:500, overnight, 4  °C). HRP-conjugated secondary 
antibody (30 min, room temperature) and black colored 
nickel–cobalt enhanced diaminobenzidine (7 min, room 
temperature) were used to visualize the labeling. Light 
microscopic examination was performed using a Nikon 
Eclipse Ni Microscope (Nikon Instruments, Amstelveen, 
Netherlands) and a digital image of the LV area of inter-
est was captured in each section (from each animal) using 
Nikon DS-RI2 camera (Nikon Instruments) and imaging 
software at 100× magnification. Staining intensity was 
determined using ImageJ Software (National Institutes 
of Health, Bethesda, MD, USA). The percentage of posi-
tively stained tissue area to total LV area of each image 
was calculated. Immunohistochemical evaluation was 
performed by a person blinded to the study groups.
In vitro organ bath experiments
Sections of the thoracic aortas were harvested from 
healthy rats as described previously [13], and were incu-
bated in either DMSO or 10 µM canagliflozin (a clinically 
relevant plasma concentration [14]) for 30  min, respec-
tively (for each group: n = 10 aortic rings). After wash-
ing and equilibration, rings were pre-constricted with 
PE  (10−6  M), and relaxation responses were examined 
by adding cumulative concentrations of the endothe-
lium-dependent vasodilator ACh  (10−9–10−4  M). 
Following PE-induced re-constriction, cumulative con-
centrations of the endothelium-independent vasodilator 
SNP  (10−10–10−5 M) were added. Half-maximal response 
 (EC50) values were obtained from individual concentra-
tion–response by fitting experimental data to a sigmoidal 
equation. The sensitivity to vasodilators was assessed by 
 pD2 = − logEC50  (M), vasorelaxation (and its maximum 
(Rmax) is expressed as percentage of the contraction 
induced by PE.
Serum and urine measurements
Serum and urine samples were collected from animals 
after the protocol, and markers of hepatic and renal func-
tion as well as serum troponin-T were determined in the 
Central Laboratory of Heidelberg University Hospital 
(Heidelberg, Germany). Serum troponin-T levels were 
analysed using the Troponin T hs STAT Reagent Kit 
(#05092728; Roche Diagnostics Gmbh, Mannheim, Ger-
many) according to the manufacturer’s protocol.
Statistical analysis
All values are expressed as mean ± SEM. Statistical analy-
sis was performed with GraphPad Prism 7 (GraphPad 
Software Inc., San Diego, CA, USA). Normal distribu-
tion of the data was evaluated by Shapiro–Wilk test. 
Significance of differences between two groups was 
assessed using unpaired two-sided Student t-test. In case 
of four groups, two-way analysis of variance (ANOVA) 
was performed with the factors ‘IRI’ (ischemia–reperfu-
sion injury;  PIRI) and ‘CANA’ (canagliflozin treatment; 
 PCANA), and their interaction  (Pint) was evaluated. In case 
of two-way ANOVA, Tukey’s post hoc test was applied to 
examine intergroup differences. A value of P < 0.05 was 
considered statistically significant.
Results
Acute canagliflozin treatment decreased myocardial infarct 
size
A single intravenous bolus of canagliflozin 5 min after the 
onset of ischemia resulted in a ~ 30% IS reduction com-
pared to vehicle (42.5 ± 2.9% vs. 59.3 ± 4.2%, P = 0.006), 
while the size of the area distal to the occlusion (i.e. 
AAR) did not differ (Fig.  1). Canagliflozin significantly 
(P = 0.048) reduced the myocardial necrosis marker 
serum troponin-T level (Fig. 1).
Acute canagliflozin treatment alleviated left ventricular 
systolic and diastolic dysfunction following ischemia–
reperfusion injury
Without affecting heart rate (Fig. 2a), canagliflozin pro-
moted LV functional recovery following IRI reflected by 
significantly (P = 0.045) increased RPP compared with 
vehicle, and effectively alleviated systolic dysfunction 
shown by preserved LV end-systolic pressure and dP/
dtmax (Fig. 2b). In case of LV end-systolic pressure and 
RPP, there was a significant interaction  (Pint = 0.007, 
respectively) between the factors of IRI and canagli-
flozin treatment, suggesting a disease-specific effect 
of the medication (Fig.  2b). Because the latter param-
eters are dependent on pre- and afterload, we recorded 
load-independent, sensitive contractility indices. In 
vehicle-treated MI rats, we observed a significant 
(P < 0.05, respectively) reduction in the value of ESPVR 
(Fig.  2d) and PRSW (Fig.  2f ) compared with sham 
operated littermates. On the contrary, canagliflozin 
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kept ESPVR values on a level comparable to that of 
controls. Furthermore, canagliflozin maintained a sig-
nificantly (P = 0.010) higher PRSW compared to vehi-
cle-treated MI rats, which was a disease-specific effect 
 (Pint = 0.013) (Fig. 2f ).
TauWeiss, which is a sensitive index of active relaxa-
tion, was significantly (P = 0.027) prolonged in vehicle-
treated MI rats, reflecting a compromised LV diastolic 
function (Fig. 2g). On the contrary, canagliflozin treat-
ment prevented the prolongation of  TauWeiss. The value 
of EDPVR (stiffness marker) was increased (P = 0.057) 
in vehicle-treated infarcted rats but remained compa-
rable to that of controls with canagliflozin treatment 
(Fig. 2e).
VAC is a ratio that represents the coupling between 
LV contractility and arterial afterload. VAC was found 
to be significantly (P = 0.018) impaired in vehicle-
treated MI rats but was substantially (P = 0.022) allevi-
ated by canagliflozin treatment (Fig.  2h). Consistently, 
LV mechanical efficiency was optimized by canagliflo-
zin treatment following IRI (Fig. 2h).
Acute canagliflozin treatment modulated phosphorylation 
of cardioprotective signalling mediators
A single intravenous bolus of canagliflozin had a major 
 (PCANA < 0.001) impact on phosphorylation of AMPK at 
the Thr172 activation site compared with vehicle treat-
ment, which effect was not disease-specific  (Pint = 0.11) 
(Fig.  3a). Accordingly, canagliflozin had a significant 
 (PCANA = 0.004) impact on the phosphorylation of the 
downstream ACC at the AMPK specific Ser79 residue, 
with significant (P = 0.025) difference between canagli-
flozin-treated versus vehicle-treated MI rats (Fig.  3b), 
suggesting an increased activation of AMPK in infarcted 
rats. Phosphorylation of eNOS at the Ser1177 residue is 
crucial for nitric-oxide (NO) production [15]. Canagliflo-
zin treatment had a significant  (PCANA = 0.013) impact on 
eNOS phosphorylation, which was not disease-specific 
 (Pint = 0.88) (Fig.  3c). Myocardial IRI had a significant 
 (PIRI < 0.001) negative effect on eNOS phosphorylation, 
which was substantially (P < 0.001) lower in the vehicle-
treated MI group compared to that of sham-operated rats 
(Fig.  3c). However, canagliflozin prevented IRI-induced 
Fig. 1 Measurement of myocardial infarct size and serum troponin‑T. Myocardial infarct size of vehicle‑treated (IRI, n = 7) and canagliflozin‑treated 
(IRI + cana, n = 7) rats with myocardial infarction is depicted as percentage of area at risk. Area at risk (the area distal to the occlusion) is expressed 
as the percentage of the total ventricular area in each group. Serum troponin‑T values of these groups are depicted. Student t‑test P values are 
reported with ticked lines between two groups. cana canagliflozin, IRI ischemia–reperfusion injury
(See figure on next page.)
Fig. 2 In vivo left ventricular (LV) pressure–volume (PV) analysis. a Heart rate values. b Preload‑dependent LV contractility indices. c Representative 
PV loops from one representative animal of each group recorded during the transient occlusion of the inferior vena cava. d, f Preload‑independent 
LV contractility indices. e, g Markers of LV diastolic function. h Indices of LV mechanoenergetics. The number of rats in each experimental group: 
sham + vehicle (n = 7); sham + canagliflozin (n = 7); IRI + vehicle (n = 9); IRI + canagliflozin (n = 10). Two‑way analysis of variance (ANOVA) P values 
(with factors: ischemia–reperfusion injury  [PIRI] and canagliflozin treatment  [PCANA]; and their interaction  [Pint]) are depicted under the title of 
each graph for the given variable. Tukey’s post hoc P values are reported with ticked lines between two groups or as follows: *P < 0.05 versus 
sham + vehicle; $P < 0.05 versus IRI + vehicle. dP/dtmax maximal slope of systolic pressure increment; EDPVR end‑diastolic PV relationship, ESPVR slope 
of the end‑systolic PV relationship, IRI ischemia–reperfusion injury, TauWeiss time constant of LV pressure decay
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reduction of eNOS phosphorylation (Fig. 3c), reflecting a 
maintained NO production.
In canagliflozin-treated MI rats, the phosphorylation of 
Akt (a well-known cardioprotective mediator in the set-
ting of acute myocardial IRI) was significantly (P = 0.024) 
higher compared to sham-operated rats (Fig. 3d). Nota-
bly, canagliflozin did not increase phosphorylation of Akt 
in healthy rats (Fig. 3d).
Acute canagliflozin treatment reduced expression 
of apoptotic and nitro‑oxidative stress markers, 
and reduced myocardial 4‑hydroxynonenal positivity
The ratio of the relative mRNA expression of the pro-
apoptotic Bax and anti-apoptotic Bcl-2 was significantly 
(P = 0.011) elevated in the vehicle-treated MI group com-
pared with the sham-operated group (Fig.  4a). In MI rats, 
canagliflozin treatment kept Bax/Bcl-2 mRNA expression 
levels comparable to that of controls (Fig. 4a). Protein expres-
sion analysis of the Bax/Bcl-2 ratio showed a significant 
(P = 0.039) increase in non-treated MI hearts, which was 
significantly (P = 0.014) reduced by canagliflozin treatment 
(Fig. 4a). This was a disease-specific effect  (Pint = 0.009).
Canagliflozin treatment reduced  (PCANA < 0.05, respec-
tively) the mRNA expression of genes related to nitro-
oxidative stress:  p47phox, SOD2, and catalase (Fig.  4b), 
which was not a disease-specific effect. Furthermore, 
vehicle-treated infarcted hearts had a significantly 
(P = 0.027) higher level of HNE positivity compared to 
sham-operated controls. On the contrary, canagliflozin 
treatment in the infarcted group significantly (P = 0.037) 
lowered the level of LV HNE positivity compared to vehi-
cle treatment (Fig. 4c).
Preincubation with canagliflozin promoted 
endothelium‑dependent vasorelaxation in aortic rings 
of healthy rats
During LV functional PV analysis, tendential reduction in 
LV end-systolic pressure and arterial elastance was found 
in canagliflozin-treated sham-operated (sham + canagli-
flozin) rats compared to vehicle-treated sham-operated 
(sham + vehicle) littermates (Fig.  5a). In order to investi-
gate whether this afterload reduction derived from a direct 
vasoactive property of the drug, we carried out organ 
bath measurements with healthy aortic rings. Compared 
to vehicle (DMSO), canagliflozin preincubation signifi-
cantly (P = 0.006) increased sensitivity of aortic rings to 
ACh-induced vasorelaxation  (pD2 to ACh) as well as the 
maximal vasorelaxation  (Rmax to ACh, P = 0.036) (Fig. 5b), 
indicating an enhanced endothelium-dependent nitric-
oxide (NO) mediated vasorelaxation. Canagliflozin had no 
effect on endothelium-independent vasodilation (Fig. 5c).
Acute canagliflozin treatment did not alter blood and urine 
glucose levels and had no adverse effect on hepatic 
and renal function
Canagliflozin had no effect on blood and urinary glucose 
in normoglycemic rats (Table 1). Treatment was not asso-
ciated with hepatic or renal injury reflected by the serum 
and urinary markers (Table 1).
Fig. 3 Effect of canagliflozin treatment on the phosphorylation of AMPK, ACC, eNOS and Akt. a Representative blots and quantification of 
phosphorylation of AMPK at the Thr172 activation site normalized to total AMPK expression. b Representative blots and quantification of 
phosphorylation of ACC at the AMPK specific Ser79 residue normalized to total ACC expression. c Representative blots and quantification of 
phosphorylation of eNOS at the Ser1177 residue normalized to total eNOS expression. d Representative blots and quantification of phosphorylation 
of Akt at the Ser473 residue normalized to total Akt expression. The number of rats in each experimental group: sham + vehicle (n = 7); 
sham + canagliflozin (n = 7); IRI + vehicle (n = 9); IRI + canagliflozin (n = 10). Two‑way analysis of variance (ANOVA) P values (with factors: ischemia–
reperfusion injury  [PIRI] and canagliflozin treatment  [PCANA]; and their interaction  [Pint]) are depicted under the title of each graph for the given 
variable. Tukey’s post hoc P values are reported as follows: *P < 0.05 versus sham + vehicle; $P < 0.05 versus IRI + vehicle. ACC acetyl‑CoA carboxylase, 
AMPK adenosine monophosphate (AMP)‑activated protein kinase, eNOS endothelial nitric‑oxide synthase
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Fig. 4 Effect of canagliflozin treatment on apoptotic and oxidative stress markers. a mRNA expression of Bax normalized to that of Bcl‑2. Protein 
expression analysis depicts representative blots and quantification of Bax expression normalized to that of Bcl‑2. b mRNA expression analysis of 
 p47phox, SOD2 and catalase normalized to the housekeeping RPL27, respectively. c Quantification and representative sections of 4‑hydroxynonenal 
(HNE) staining of the LV. The number of rats in each experimental group: sham + vehicle (n = 7); sham + canagliflozin (n = 7); IRI + vehicle (n = 9); 
IRI + canagliflozin (n = 10). Two‑way analysis of variance (ANOVA) P values (with factors: ischemia–reperfusion injury  [PIRI] and canagliflozin treatment 
 [PCANA]; and their interaction  [Pint]) are depicted under the title of each graph for the given variable. Tukey’s post hoc P values are reported as follows: 
*P < 0.05 versus sham + vehicle; $P < 0.05 versus IRI + vehicle. Bax = B‑cell leukemia/lymphoma 2 associated protein x; Bcl2 B‑cell leukemia/lymphoma 
2, p47phox the 47 kDa subunit of the multiprotein complex nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, SOD2 superoxide 
dismutase‑2
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Fig. 5 Effect of canagliflozin on vasorelaxation. a End‑systolic blood pressure and arterial elastance of vehicle‑treated (sham + vehicle, n = 7) and 
canagliflozin‑treated (sham + canagliflozin, n = 7) healthy (sham‑operated) rats from the second part of the in vivo study. b Effect of canagliflozin 
on endothelium‑dependent vasorelaxation in healthy aortic rings in vitro (n = 10 aortic rings in each group). c Effect of canagliflozin on 
endothelium‑independent vasorelaxation in healthy aortic rings in vitro (n = 10 aortic rings in each group). Student t‑test P values are reported 
with ticked lines between two groups or as: *P < 0.05. ACh acetylcholine, cana canagliflozin, DMSO dimethyl sulfoxide, pD2 − logEC50, Rmax maximal 
vasorelaxation, SNP sodium nitroprusside
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Discussion
For the first time, we demonstrated that the intravenous 
administration of the SGLT2 inhibitor canagliflozin after 
the onset of ischemia protected against in vivo myocar-
dial IRI in non-diabetic rats. Canagliflozin increased the 
phosphorylation of cardioprotective signalling media-
tors while reducing the expression of apoptotic and 
nitro-oxidative stress markers. Accordingly, canagliflozin 
prevented the development of systolic and diastolic dys-
function following IRI. The medication had a slight blood 
pressure and LV afterload lowering effect in healthy rats, 
and enhanced endothelium-dependent vasorelaxation in 
aortic rings.
The main antidiabetic action of SGLT2 inhibitors in 
T2DM derives from the blockade of glucose reabsorption 
in the proximal tubule of the kidney. According to Zel-
niker and Braunwald [5], SGLT2 inhibition in the kidney 
does not serve as full explanation for the stunning cardio-
vascular protection afforded by SGLT2 inhibitors in clini-
cal trials, yet other effects than their antihyperglycemic 
actions are poorly understood. The CANVAS Program 
clinical trial showed fast separation of event curves in 
canagliflozin-treated T2DM patients compared to pla-
cebo, and outstanding reduction in hospitalization for 
HF [2] (especially in those with HF at baseline [3]), that 
was also documented in a real-world study (CVD-REAL) 
[16]. These findings suggest that the cardioprotective 
effect of canagliflozin might be partly independent of its 
antidiabetic action. This is of particular interest, since the 
mRNA expression of SGLT2 in the human heart is neg-
ligible [17], suggesting potential off-target effects of the 
medication.
In the present study we found that a single intravenous 
bolus of canagliflozin affected AMPK activation inde-
pendently of antidiabetic action in rats with healthy and 
infarcted hearts. This finding contributes to previous pre-
clinical experiments which have shown that canagliflo-
zin potently and immediately activates AMPK in cancer 
cells [18], murine hepatocytes [6], and human endothelial 
cells [19]. Studies have shown that AMPK activation has 
beneficial effects in various cardiovascular diseases [20]. 
Specifically, pharmacological AMPK activation has been 
documented to protect against myocardial IRI in non-
diabetic [21] and diabetic [22] mice, which was mediated 
by increased eNOS phosphorylation. Here we present 
that canagliflozin increased the activation of AMPK 
given after the onset of ischemia (in a clinically relevant 
fashion), as evidenced by a significant upregulation of the 
phosphorylation of ACC at the AMPK specific site. The 
medication prevented the reduction of eNOS phospho-
rylation following IRI compared to vehicle, suggesting a 
preserved NO signaling. Maintained NO signaling has 
been previously shown to reduce apoptosis, myocardial 
nitro-oxidative stress and platelet aggregation, conferring 
protection against myocardial IRI [23]. Akt (also referred 
to as protein kinase B) has also been implicated as a cru-
cial mediator of cardioprotection during myocardial IRI, 
and has been demonstrated to phosphorylate eNOS at 
the same site (Ser1177) as AMPK [24]. We found a sig-
nificantly increased Akt phosphorylation in canagliflo-
zin-treated infarcted hearts compared to sham-operated 
controls. It is not clear from our study as to what extent 
AMPK or Akt activation contributed to the preserved 
phosphorylation of eNOS in the infarcted hearts, and 
Table 1 Serum and urine parameters
Canagliflozin did not alter serum and urine glucose levels in non-diabetic rats, and was not associated with hepatic or renal injury
To investigate intergroup differences, Tukey’s post hoc test was performed following two-way analysis of variance (ANOVA). *P < 0.05 versus sham + vehicle; IRI 
ischemia–reperfusion injury
Parameters Sham + vehicle Sham + canagliflozin IRI + vehicle IRI + canagliflozin
Serum glucose (mg/dL) 215 ± 15 193 ± 10 205 ± 13 226 ± 17
Urine glucose (mmol/L) 0.54 ± 0.06 0.49 ± 0.06 0.44 ± 0.06 0.52 ± 0.04
Serum creatine kinase (IU/L) 1778 ± 247 1806 ± 346 3445 ± 436* 3089 ± 477
Serum lactate dehydrogenase (IU/L) 961 ± 81 789 ± 41 3279 ± 259* 2716 ± 242*
Serum aspartate transaminase (IU/L) 217 ± 23 191 ± 10 899 ± 119* 745 ± 91*
Serum alanine transaminase (IU/L) 63 ± 4 57 ± 5 131 ± 11* 114 ± 12*
Alkaline phosphatase (IU/L) 268 ± 10 277 ± 13 273 ± 13 304 ± 15
Cholesterol (mg/dL) 79 ± 4 82 ± 4 78 ± 4 77 ± 2
Creatinine (mg/dL) 0.47 ± 0.05 0.42 ± 0.02 0.58 ± 0.08 0.55 ± 0.05
Urinary urea nitrogen (g/dL) 27 ± 5 26 ± 3 21 ± 4 20 ± 2
Urinary creatinine (mg/dL) 103 ± 9 115 ± 11 116 ± 12 99 ± 8
Urinary albumin (mg/L) 16 ± 3 13 ± 6 16 ± 4 15 ± 3
Page 12 of 14Sayour et al. J Transl Med          (2019) 17:127 
further studies are warranted to elucidate this. Both 
AMPK [25] and Akt [26] have been previously implicated 
in reducing cell death during myocardial ischemia–rep-
erfusion. In the present study, canagliflozin decreased 
the ratio of Bax/Bcl-2 expression on the mRNA and pro-
tein levels following myocardial IRI, suggesting reduced 
apoptotic activity in the AAR compared to vehicle treat-
ment. Accordingly, we report a ~ 30% reduction in infarct 
size and serum troponin-T levels in canagliflozin-treated 
infarcted rats compared to vehicle-treated ones.
Oxidative stress is a key mediator of myocardial IRI as 
it contributes to cell death and affects myocardial infarct 
size [27]. In our study, canagliflozin treatment reduced the 
mRNA expression of  p47phox (subunit of the pro-oxidative 
NADPH oxidase), SOD2 and catalase in the myocardium, 
which is in good agreement with a previous study in which 
pharmacological activation of AMPK downregulated 
the expression of these enzymes following renal IRI [28]. 
To further elucidate the possible antioxidative effect of 
canagliflozin, we performed immunohistochemical stain-
ing for HNE. The burst of reactive oxygen species during 
myocardial IRI results in lipid peroxidation, during which 
the most toxic aldehydic end-product, HNE, accumulates. 
In the myocardium, evidence shows that HNE disrupts 
enzymatic and mitochondrial functions [29]. Hence, the 
level of HNE production has been shown to correlate with 
the extent of myocardial IRI in terms of functional recov-
ery [30]. In the present study, we documented a signifi-
cantly lower HNE positivity in the canagliflozin-treated 
infarcted hearts compared to vehicle-treated ones. This 
might reflect that canagliflozin reduced myocardial oxi-
dative stress, contributing to an enhanced LV functional 
recovery following myocardial IRI.
The present study provides a detailed functional 
analysis of healthy and infarcted rat hearts, treated 
with either vehicle or canagliflozin. We show that a sin-
gle bolus of intravenous canagliflozin given in a clini-
cally relevant approach (i.e. after the onset of ischemia) 
substantially improved recovery of the myocardium 
following IRI, as evidenced by significantly higher 
RPP and increased LV end-systolic pressure and dP/
dtmax. These are in accordance with a previous study, 
in which a pharmacological AMPK activator increased 
RPP following IRI, indicating an improved LV recovery 
[21]. The values of ESPVR and PRSW, which are load-
independent sensitive contractility indices, showed 
a marked amelioration in canagliflozin-treated MI 
rats compared to vehicle-treated ones. These findings 
reflect the protective effect of canagliflozin against the 
development of LV systolic dysfunction. Accordingly, 
we found a significantly improved VAC in canagliflozin-
treated infarcted hearts compared to vehicle-treated 
ones, suggesting a more physiological matching 
between LV contractility and arterial afterload. Regard-
ing diastolic function, we found a severely compro-
mised LV stiffness (EDPVR) and active relaxation 
 (TauWeiss) in rats with acute MI. However, canagliflozin 
normalized EDPVR and prevented the prolongation of 
the time-constant of active relaxation  (TauWeiss), sug-
gesting a preserved LV diastolic function following 
IRI. Finally, the severe attenuation of LV mechanical 
efficiency in vehicle-treated infarcted hearts was pre-
vented by canagliflozin treatment, indicating decreased 
oxygen consumption of the myocardium to maintain 
cardiac output.
In healthy non-diabetic rats, we show that acute cana-
gliflozin treatment slightly decreased systolic blood 
pressure and the afterload index arterial elastance 
without inducing reflex tachycardia. Canagliflozin 
treatment reduced systolic blood pressure in T2DM 
patients in the clinical setting at very early stages [2, 
31]. In previous preclinical studies, a possible effect of 
canagliflozin on vasorelaxation was assessed. Canagli-
flozin incubation was found to induce vasorelaxation in 
pulmonary but not coronary artery rings from diabetic 
mice [8], and increased vasorelaxation response to ACh 
in hyperglycemic aortic rings [9]. These findings sug-
gest a direct vascular effect of canagliflozin that is not 
related to antihyperglycemic effect. Indeed, in ex  vivo 
non-diabetic mouse hearts, canagliflozin preincubation 
significantly reduced perfusion pressure, suggesting 
enhanced coronary vasodilation [7]. Further contrib-
uting to these findings, here we report that preincuba-
tion of aortic rings of non-diabetic rats with a clinically 
relevant concentration of canagliflozin enhanced vas-
orelaxation sensitivity to ACh and increased overall 
maximal relaxation of the rings, indicating that canagli-
flozin might have a direct vasorelaxant effect indepen-
dently of its antidiabetic action. This might explain why 
a tendential reduction in cardiac afterload was seen in 
healthy treated rats in vivo.
Our study has limitations. First, we cannot rule out 
the influence of cardioprotective molecular mecha-
nisms other than those investigated in the present 
work, which could have contributed to the cardiopro-
tection exerted by canagliflozin. Accordingly, further 
studies are required to ascertain the involvement of 
such pathways. Second, we tested the medication only 
in male non-diabetic rats. Additional experiments are 
warranted to characterize possible sex-specific differ-
ences regarding the cardioprotective effect of cana-
gliflozin and to investigate whether it protects against 
myocardial IRI in diabetic rats.
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Conclusions
The impressive cardiovascular protective effects of 
canagliflozin in T2DM patients reported in clinical 
trials seem to be partly independent of its antihyper-
glycemic action, because canagliflozin affects cardio-
protective signalling in non-diabetic rats, and enhances 
endothelium-dependent vasorelaxation. Accordingly, 
canagliflozin protected against myocardial IRI and alle-
viated systolic and diastolic dysfunction.
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